Lumora agrees licence and development program for Veterinary applications with Biogal Galed Labs

Cambridge, UK, Tuesday 28th May 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has entered into a license and development agreement with Biogal Galed Labs ACS Ltd, a provider of veterinary diagnostics, to develop a series of veterinary tests.

The partnership will allow Biogal Galed Labs ACS Ltd to access Lumora’s enabling technologies such as BART (Bioluminescent Assay in Real Time), as well as  the company’s proven know-how in test development, reader technologies and manufacturing.

The partnership will involve a significant pipeline of test development, starting with Leptosporis, a zoonotic bacterial infection transmitted through the urine of animals. Financial details were not disclosed.

Hayden Jeffreys, Commercial Director at Lumora, said: “This partnership further illustrates the broad utility of Lumora’s technology. The simplicity, robustness and ease of use, make BART and our other technologies very applicable to the non-traditional molecular environment, whether this in the industrial applications or in the clinical market.”

Laurence Tisi, CEO of Lumora, added:  “This deal with Biogal will showcase the benefits of working with Lumora’s expert team and its focus on delivering partner’s products to market in the shortest time possible.  With the Leptosporosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline.”

A spokesperson from Biogal commented, “We are excited to be able to partner with Lumora. They have an excellent track record of producing high quality assays for their partners, across a wide range of applications. Through this partnership we aim to provide our customers with advanced diagnostics which can be provided in all sizes of veterinary labs.”

The deal with Biogal follows a series of milestones for Lumora this year, including a partnership with FIND (Foundation for Innovative Novel Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.


For further information please contact:

Tony Stephenson, Director

Exitus Communications

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.



Notes to Editors: 


Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

Biogal Galed Labs ACS Ltd

Biogal, is a private company owned by Kibbutz Galed and is headquartered in northern Israel. It was established in 1986.Biogal – Galed Laboratories is dedicated to the development, manufacturing and marketing of excellent diagnostic tools for companion animals, poultry, farm animals and laboratory rodents. Customer oriented services lead us forward in our search for excellence, efficiency and innovation.